Currently, there are 1.25B common shares owned by the public and among those 1.24B shares have been available to trade.
The company’s stock has a 5-day price change of 1.05% and 27.97% over the past three months. GILD shares are trading 26.89% year to date (YTD), with the 12-month market performance up to 61.38% higher. It has a 12-month low price of $62.07 and touched a high of $118.42 over the same period. GILD has an average intraday trading volume of 7.72 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.85%, 17.14%, and 38.21% respectively.
Institutional ownership of Gilead Sciences, Inc (NASDAQ: GILD) shares accounts for 86.62% of the company’s 1.25B shares outstanding.
It has a market capitalization of $145.97B and a beta (3y monthly) value of 0.33. The stock’s trailing 12-month PE ratio is 319.29, while the earnings-per-share (ttm) stands at $0.37. The company has a PEG of 12.94 and a Quick Ratio of 1.45 with the debt-to-equity ratio at 1.41. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.62% over the week and 2.38% over the month.
Earnings per share for the fiscal year are expected to increase by 72.19%, and 5.98% over the next financial year. EPS should grow at an annualized rate of 24.67% over the next five years, compared to -38.13% over the past 5-year period.
Looking at the support for the GILD, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on March 04, 2025, with the firm’s price target at $115-$132. Deutsche Bank coverage for the Gilead Sciences, Inc (GILD) stock in a research note released on February 18, 2025 offered a Buy rating with a price target of $120. DZ Bank was of a view on February 13, 2025 that the stock is Buy, while Morgan Stanley gave the stock Overweight rating on January 10, 2025, issuing a price target of $87- $113. BofA Securities on their part issued Buy rating on December 10, 2024.
